Chugai Pharmaceutical Co., Ltd. · TSE:4519

Chugai Pharmaceutical — Q1 2015 Earnings Presentation

19 slides from Chugai Pharmaceutical's earnings presentation, Apr 22, 2015

  1. Slide 1: FY2015 1Q Consolidated Financial Overview (IFRS based)

    Slide 1: FY2015 1Q Consolidated Financial Overview (IFRS based)

    FY2015 1Q Consolidated Financial Overview (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. Vice President General Manager of Finance & Accounting Dept. Toshiaki Itagaki April 22, 2015

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FY2015 1Q Consolidated Financial Overview Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information a

  3. Slide 3: 1Q Results Summary

    Slide 3: 1Q Results Summary

    FY2015 1Q Consolidated Financial Overview 1Q Results Summary  Revenues: 117.1 billion yen (-6.9, -5.6% YoY) • Domestic sales excl. Tamiflu: steady increase if the impact of last year’s temporary demand prior to the consumption tax increase is excluded (-1.3, -1.5%) • Overseas sales: increase due to

  4. Slide 4: IFRS and Core Results Jan – Mar

    Slide 4: IFRS and Core Results Jan – Mar

    FY2015 1Q Consolidated Financial Overview IFRS and Core Results Jan – Mar IFRS results Non-core items Core results (Billions of JPY) (Billions of JPY) 2015 Intangible assets Other 2015 and Business eliminated Non-Core items Jan - Mar combinations items Jan - Mar 1. Intangible/Business combinations A

  5. Slide 5: Financial Overview Jan – Mar

    Slide 5: Financial Overview Jan – Mar

    FY2015 1Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan – Mar 2014 2015 (Billions of JPY) Jan - Mar Jan - Mar Growth (Billions of JPY) vs. Revenues vs. Revenues Revenues 124.0 117.1 -6.9 -5.6% Royalties and other operating income -6.1 Sales 114.2 113.4 -0.8 -0.7% milesto

  6. Slide 6: Sales (excl. Tamiflu) Jan – Mar

    Slide 6: Sales (excl. Tamiflu) Jan – Mar

    FY2015 1Q Consolidated Financial Overview Year on Year Sales (excl. Tamiflu) Jan – Mar Sales by Disease Area, Sales by Products, Year on Year Comparisons Year on Year Changes (Billions of JPY) 107.3 -0.6, -0.6% 106.7 Overseas -0.9 Mircera Kadcyla +0.7, +3.2% (5.0) (1.5) +1.5 22.1 22.8 Others -0.7 Pe

  7. Slide 7: Tamiflu Sales Performance

    Slide 7: Tamiflu Sales Performance

    FY2015 1Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales Forecast (Billions of JPY) FY2009.12 FY2010.12 FY2011.12 FY2012.12 FY2013.12 FY2014.12 FY2015.12 Cases per Seasonal sentinel* Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun

  8. Slide 8: Operating Profit Jan – Mar

    Slide 8: Operating Profit Jan – Mar

    FY2015 1Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan – Mar (Billions of JPY) 2014 2015 (Billions of JPY) Growth Gross profit Jan - Mar Jan - Mar from sales Revenues 124.0 117.1 -6.9 Cost of sales -55.3 -57.4 -2.1 -3.0 Royalties and other Gross profit 68.8 59.7 -9.1 oper

  9. Slide 9: Financial Progress Jan – Mar

    Slide 9: Financial Progress Jan – Mar

    FY2015 1Q Consolidated Financial Overview vs. Forecast (Core) Financial Progress Jan – Mar Actual Forecast on Jan 28 2014 (Billions of JPY) 2015 2015 Progress Progress * Jan - Mar Jan - Dec Revenues 117.1 486.5 24.1% 26.9% Sales 113.4 460.8 24.6% 26.1% excl. Tamiflu 106.7 453.4 23.5% 25.3% Domestic

  10. Slide 10: Sales Progress (excl. Tamiflu) Jan – Mar

    Slide 10: Sales Progress (excl. Tamiflu) Jan – Mar

    FY2015 1Q Consolidated Financial Overview vs. Forecast (Core) Sales Progress (excl. Tamiflu) Jan – Mar Actual Full-year forecast 2014 (Billions of JPY) 2015 2015 Progress Progress * Jan - Mar Jan - Dec Sales excl. Tamiflu 106.7 453.4 23.5% 25.3% Domestic 83.9 360.9 23.2% 24.4% Oncology 47.7 204.5 23

  11. Slide 11: Impact from Foreign Exchange

    Slide 11: Impact from Foreign Exchange

    FY2015 1Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange [Reference] Historical exchange rate to the JPY FX impact Jan - Mar (Billions of JPY) (vs. Forecast on Jan. 28) JPY 2015 EUR 2015 CHF 2014 EUR 2014 CHF 150 +0.6 145 140 Revenues Sales +0.7 135 Royalties and ot

  12. Slide 12: Overview of Development Pipeline

    Slide 12: Overview of Development Pipeline

    Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Associate Vice President Deputy Head of Project & Lifecycle Management Unit Department Manager of R&D Portfolio Management Dept. Minoru Watanabe 2015.4.22

  13. Slide 13: Oncology Field Projects under Development

    Slide 13: Oncology Field Projects under Development

    Overview of Development Pipeline Oncology Field Projects under Development (as of 22 April, 2015) Phase I Phase II Phase III Filed CKI27 / RG7304 RG435 / Avastin AF802 (RG7853) RG340 / Xeloda (Japan / overseas) - cervical cancer / Alecensa (overseas) - gastric cancer (adjuvant) - solid tumors - NSCL

  14. Slide 14: Primary Field Projects under Development

    Slide 14: Primary Field Projects under Development

    Overview of Development Pipeline Primary Field Projects under Development (as of 22 April, 2015) Phase I Phase II Phase III Filed RG484 / Bonviva (oral) Bone & Joint - osteoporosis★ MRA / Actemra MRA / Actemra (overseas) - large-vessel vasculitis - systemic sclerosis MRA / Actemra Autoimmune (overse

  15. Slide 15: Development Status

    Slide 15: Development Status

    Overview of Development Pipeline Development Status In- RG7204 / Zelboraf ® licensed Unresectable melanoma with BRAF mutation Launched in February 2015 In- RG484 / Bonviva® (oral) licensed Osteoporosis Filed in February 2015 In- MRA / Actemra® house Subcutaneous injection formulation for rheumatoid

  16. Slide 16: Other Progress

    Slide 16: Other Progress

    Overview of Development Pipeline Other Progress In- RG7446 / MPDL3280A (Engineered anti-PDL1 antibody) licensed Non-small cell lung cancer (1st line) Decided to participate in 3 multinational studies February 2015 U.S. FDA grants Breakthrough Therapy Designation in non-small cell lung cancer (Roche)

  17. Slide 17: Upcoming Events (Planned)

    Slide 17: Upcoming Events (Planned)

    Overview of Development Pipeline Upcoming Events (Planned) In- RG484 / Bonviva® (oral): March 2015 licensed Results of Japanese P3 study for osteoporosis presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases • Primary endpoint achieved by demonstrating a non-in

  18. Slide 18: Projected Submissions (Post PoC NMEs and Products)

    Slide 18: Projected Submissions (Post PoC NMEs and Products)

    Overview of Development Pipeline Projected Submissions (Post PoC N M Es and Products)  Seamless filings every year ACE910 NME line extension Hemophilia A in-house in-licensed lebrikizumab (RG3637) IPF lebrikizumab gantenerumab BONVIVA (RG3637) (RG1450) (RG484) Asthma Alzheimer’s disease Osteoporosi

  19. Slide 19: Contacts: Corporate Communications Dept.

    Slide 19: Contacts: Corporate Communications Dept.

    Contacts: Corporate Communications Dept. Media Relations Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp Koki Harada, Hiroshi Araki, Sachiyo Yoshimura, Chisato Miyoshi Investor Relations Group Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail: ir@chugai-pharm

Source: Internet Archive copy of chugai-pharm.co.jp

More decks from Chugai Pharmaceutical Co., Ltd.

All 107 Chugai Pharmaceutical decks